MyoKardia begins dosing in Phase I trial of MYK-491 to treat DCM

US-based clinical stage biopharmaceutical firm MyoKardia has begun dosing in its Phase I single ascending dose clinical study of MYK-491 to treat dilated cardiomyopathy (DCM).

Source: Drug Development Technology - February 6, 2017 Category: Pharmaceuticals Source Type: news